CANF—All in all, even if used pre and post anti-TNFs, I don't expect [CF101] to have a substantial market uptake in RA (I see a better future for it in psoriasis).
Can you elaborate on your reasons? Psoriasis has become almost as competitive a marketplace as RA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.